#Eurofins

[eurofinsadvinus]

𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐛𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬 𝐢𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐢𝐦𝐦𝐮𝐧𝐨-𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 requires precision and a comprehensive approach. We're dedicated to providing you with the tailored solutions and expert support needed to advance your drug development journey. From predictive in vivo models to customizable study designs, we're here to help you navigate the complexities of cancer research. Let's collaborate to develop effective anti-cancer therapies. If you will be at #AACR25, do stop by booth 146 to discuss your requirements with our team. Let’s Connect – bd.pharmacology@advinus.eurofinsasia.com

[eurofinsindia]

At Eurofins, our Next Generation Sequencing (NGS) team enables researchers to make breakthroughs in diverse applications and helps scientists tackle complex biological challenges. NGS revolutionizes research by allowing you to:

🧬 Rapidly sequence entire genomes. 🔍Deeply sequence a specific target region, Utilise RNA-Seq to discover novel RNA variants or quantify mRNAs for gene expression analysis. 🧬 Analyse DNA methylation and DNA-protein interactions.   🦠 Study the microbiome and identify novel pathogens.

Learn how Eurofins Genomics is driving innovation in testing for life

[landopics]

[jcmarchi]

French initiative for responsible AI leaders - AI News

New Post has been published on https://thedigitalinsider.com/french-initiative-for-responsible-ai-leaders-ai-news/

French initiative for responsible AI leaders - AI News

ESSEC Business School and Accenture have announced the launch of a new initiative, ‘AI for Responsible Leadership,’ which marks the 10th anniversary of the establishment of the role of Chair at ESSEC, titled the ESSEC Accenture Strategic Business Analytics Chair.

The initiative aims to encourage the use of artificial intelligence by leaders in ways that are responsible and ethical, and that lead to high levels of professional performance. It aims to provide current and future leaders with the skills they require when faced with challenges in the future; economic, environmental, or social.

Several organisations support the initiative, including institutions, businesses, and specialised groups, including ESSEC Metalab for Data, Technology & Society, and Accenture Research.

Executive Director of the ESSEC Metalab, Abdelmounaim Derraz, spoke of the collaboration, saying, “Technical subjects are continuing to shake up business schools, and AI has opened up opportunities for collaboration between partner companies, researchers, and other members of the ecosystem (students, think tanks, associations, [and] public service).”

ESSEC and Accenture aim to integrate perspectives from multiple fields of expertise, an approach that is a result of experimentation in the decade the Chair has existed.

The elements of the initiative include workshops and talks designed to promote the exchange of knowledge and methods. It will also include a ‘barometer’ to help track AI’s implementation and overall impact on responsible leadership.

The initiative will engage with a network of institutions and academic publications, and an annual Grand Prix will recognise projects that focus on and explore the subject of AI and leadership.

Fabrice Marque, founder of the initiative and the current ESSEC Accenture Strategics Business Analytics Chair, said, “For years, we have explored the potential of using data and artificial intelligence in organisations. The synergies we have developed with our partners (Accenture, Accor, Dataiku, Engie, Eurofins, MSD, Orange) allowed us to evaluate and test innovative solutions before deploying them.

“With this initiative, we’re taking a major step: bringing together an engaged ecosystem to sustainably transform how leaders think, decide, and act in the face of tomorrow’s challenges. Our ambition is clear: to make AI a lever for performance, innovation and responsibility for […] leaders.”

Managing Director at Accenture and sponsor of the ESSEC/Accenture Chair and initiative, Aurélien Bouriot, said, “The ecosystem will benefit from the resources that Accenture puts at its disposal, and will also benefit our employees who participate.”

Laetitia Cailleteau, Managing Director at Accenture and leader of Responsible AI & Generative AI for Europe, highlighted the importance of future leaders understanding all aspects of AI.

“AI is a pillar of the ongoing industrial transformation. Tomorrow’s leaders must understand the technical, ethical, and human aspects and risks – and know how to manage them. In this way, they will be able to maximise value creation and generate a positive impact for the organisation, its stakeholders and society as a whole.”

Image credit: Wikimedia Commons

See also: Microsoft and OpenAI probe alleged data theft by DeepSeek

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is co-located with other leading events including Intelligent Automation Conference, BlockX, Digital Transformation Week, and Cyber Security & Cloud Expo.

Explore other upcoming enterprise technology events and webinars powered by TechForge here.

[global-testing-group]

About GTG Group

GTG Group (Global Testing Group) is China's leading testing and certification company and is accredited by local and world famous international bodies that includes: IECEE, UL, A2LA, NVLAP, ITS (Intertek), KTC, TÜV, Eurofins, CNAS, CMA, CQC.

With 10 years of experience, we have helped thousands of organizations access markets, comply, innovate, and differentiate.

Let us help you improve your products and stay ahead of your competition today!

[business-market-insight]

Europe Genomics Market Trends, Size, Segment and Growth by Forecast to 2030

Market Overview and Dynamics

The Europe Genomics market is expected to reach US$ 15,448.81million in 2027 from US$ 6,023.69million in 2019. The market is estimated to grow with a CAGR of 12.8% from 2020-2027. The growth of this market is estimated to grow owing to key driving factors such as the extensive development in research and development activities concerning genomics market and the increase in government initiatives for growth in the genomics market. However, the market growth is likely to be hindered owing to the several challenges encountered regarding genomics market. Download Full PDF Sample Copy of Market Report @- https://www.businessmarketinsights.com/sample/TIPRE00004302

Market Introduction

Genomics is defined as the study of a gene and its functioning. Genomics is used to examine the molecular mechanisms and the interaction of genetic and environmental factors in the diseases. The major factors attributing to the growth of the genomics market are growing government support and increased number of genomics studies, declining sequencing cost, increased genomics applications.

Europe Genomics Strategic Insights

Strategic insights for the Europe Genomics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Genomics Report Scope

Attribute

Details

Market Size (2019)

US$ 6,023.69 Million

Market Size (2027)

US$ 15,448.81 Million

CAGR (2020–2027)

12.8%

Historical Data

2017–2018

Forecast Period

2020–2027

Segments Covered

Technology, Product & Service, Application, End User

Technologies

Sequencing, Microarray, PCR, Nucleic Acid Extraction

Product & Service

Instruments/Systems, Consumables, Services

Applications

Diagnostics, Drug Discovery, Personalized Medicine, Agriculture Research

End Users

Research Centers, Hospitals, Pharma/Biotech Companies

Regions Covered

Europe (UK, Germany, France, Russia, Italy, Rest of Europe)

Key Companies

Illumina, Danaher, Roche, Bio-Rad, GE, Thermo Fisher, Agilent, Eurofins, QIAGEN, BGI

Europe Genomics Regional Insights

The geographic scope of the Europe Genomics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Key Market Segments

Based on technology, the genomics market is segmented into sequencing, microarray, PCR, nucleic acid extraction and purification, and others. Based on product and service, the genomics market is segmented into instruments/systems, consumables, and services.  Based on application, the genomics market, is segmented into diagnostics, drug discovery and development, precision/personalized medicine, agriculture & animal research, and others. Based on end-user, the genomics market, is segmented into research centers, hospitals and clinics, pharmaceutical & biotechnology companies, and others.

Major Sources and Companies Listed

Some of the major primary and secondary sources for genomics market included in the report are UK Synthetic Biology Strategic Plan, Precision Medicine Infrastructure Associated with Science and Technology (IMPACT), and others.

Reasons to buy the report

To understand the Europe Genomics market landscape and identify market segments that are most likely to guarantee a strong return

Stay ahead of the race by comprehending the ever-changing competitive landscape for Genomics market

Efficiently plan M&A and partnership deals in Europe Genomics market by identifying market segments with the most promising probable sales

Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Genomics market

Obtain market revenue forecast for market by various segments from 2019 to 2027 in Europe region

EUROPE GENOMICS MARKET SEGMENTATION

Category

Segments

By Technology

Sequencing, Microarray, PCR, Nucleic Acid Extraction & Purification, Others

By Product & Services

Instruments/Systems, Consumables, Services

By Application

Diagnostics, Drug Discovery & Development, Personalized Medicine, Agriculture & Animal Research, Others

By End User

Research Centers, Hospitals & Clinics, Biotech & Pharma Companies, Others

By Country (Europe)

Germany, UK, France, Spain, Italy, Rest of Europe

Company Profiles

Illumina, Danaher, F. Hoffmann-La Roche, Bio-Rad, GE

Can you see this our reports –

Europe Synthetic Biology Market — https://postyourarticle.com/europe-synthetic-biology-market-trends-size-segment-and-growth-by-forecast-to-2030-3/

North America Conveyor System Market — https://sites.google.com/view/businessmarketinsights–15/home

North America Biker Helmet Market — https://businessmarketins02.blogspot.com/2025/04/north-america-biker-helmet-market_17.html

Europe Clinical Trials Supplies Market — https://postyourarticle.com/europe-clinical-trials-supplies-market-trends-size-segment-and-growth-by-forecast-to-2030-2/

Europe Fishing Reels Market — https://www.openpr.com/news/3973744/europe-fishing-reels-market-trends-size-segment-and-growth About Us: Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications Author’s Bio Akshay Senior Market Research Expert at Business Market Insights

[industrynewsupdates]

An In-Depth Look at the Growth of Recombinant Protein Therapeutics CDMO Market

The global recombinant protein therapeutics CDMO market is expected to reach USD 52.0 billion by 2030 and is expected to expand at a CAGR of 13.95% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological innovations about the development of novel recombinant protein therapeutics and rising research and development for biologics are anticipated to influence the recombinant protein therapeutics CDMO industry positively. The development of novel recombinant protein therapeutics has observed significant advancements due to various technological innovations.

Recombinant proteins are bioengineered proteins produced by introducing the gene encoding the desired protein into a host cell, typically a microorganism or a mammalian cell, to express and produce the protein of interest. Several protein engineering platform technologies are currently employed to enhance the circulating half-life, targeting the precision and functionality of novel therapeutic protein drugs. These technologies also aim to boost production yield and ensure product purity.

Besides, the biopharmaceutical industry has witnessed significant growth, with an increasing number of companies investing in research and development of biologics, including recombinant proteins. This growth has been facilitated by advancements in manufacturing technologies, including adopting single-use bioreactors and other innovative production methods. For instance, in January 2024, Eurofins CDMO Alphora, Inc. announced the successful completion of its pilot-scale biologics development facility. With an expansive area of 3,300 square feet, this facility is exclusively dedicated to developing and scaling monoclonal antibodies (mAbs) and other therapeutic proteins derived from mammalian sources.

Moreover, the global increase in the prevalence of chronic and complex diseases, such as cancer, autoimmune disorders, & metabolic diseases, has increased the demand for innovative and effective therapeutic options. Recombinant protein therapeutics offer a diverse range of candidates to address these complex medical conditions. For instance, based on estimates from the American Cancer Society, it is projected that in 2023, there will be approximately 1,958,310 new cases of cancer and 609,820 cancer-related deaths in the U.S. Furthermore, according to a research article published by Oxford University, in June 2022, the number of approved and marketed antibody therapies reached 162, nearly half of which (42.6%) were being developed for the treatment of cancer.

In March 2023, the U.S. FDA granted accelerated clearance to Incyte Corporation's retifanlimab-dlwr for the treatment of adult patients with metastatic or recurrent, locally advanced Merkel Cell Carcinoma (MCC). Besides, biological therapy in cancer supports repairing, stimulating, or enhancing the immune response. Therefore, many pharmaceutical & biopharmaceutical companies are willing to invest in cancer-related novel treatments. Such advancements collectively aim to achieve a higher yield of quality products.

Get a preview of the latest developments in the Recombinant Protein Therapeutics CDMO Market? Download your FREE sample PDF copy today and explore key data and trends. 

Recombinant Protein Therapeutics CDMO Market Report Highlights

• The others segment dominated the market in 2023. The segment growth is driven by increasing recombinant protein therapies as a safer option than plasma-derived products owing to the potential to reduce bloodborne transmission of infectious diseases

• Based on the source, mammalian systems held the largest market share of 67.4% in 2023 attributed to an increase in the adoption of mammalian systems for sourcing recombinant proteins. Mammalian cell culture systems offer advantages in producing complex proteins with appropriate post-translational modifications, making them suitable for a wide range of therapeutic applications

• Based on indication, the metabolic disorders segment held a market share of 21.8% in 2023. The segment is driven by a growing aging population, and robust demand for pharmaceutical industry, which has contributed to its prominence in this field

• North America dominated the market with a share of 38.5% in 2023. The region has a strong R&D infrastructure and a robust biopharmaceutical industry, which has contributed to the market growth. Furthermore, the U.S. has a sophisticated and well-developed manufacturing infrastructure for biopharmaceuticals, including recombinant protein therapeutics

Recombinant Protein Therapeutics CDMO Market Segmentation

Grand View Research has segmented the global recombinant protein therapeutics CDMO market based on type, source, indication, service type, end-use, and region:

Recombinant Protein Therapeutics CDMO By Type Outlook (Revenue, USD Million, 2018 - 2030)

• Growth Hormones

• Interferons

• Vaccines

• Immunostimulating Agents

• Others

Recombinant Protein Therapeutics CDMO By Source Outlook (Revenue, USD Million, 2018 - 2030)

• Mammalian Systems

• Microbial Systems

• Others

Recombinant Protein Therapeutics CDMO By Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Infectious Diseases

• Immunological Disorders

• Metabolic Disorders

• Haematological Disorders

• Others

Recombinant Protein Therapeutics CDMO By Service Type Outlook (Revenue, USD Million, 2018 - 2030)

• Contract Manufacturing

• Contract Development

Recombinant Protein Therapeutics CDMO By End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical Companies

• Biotech Companies

• Others

Recombinant Protein Therapeutics CDMO By Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o U.K.

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

List of Key Players in the Recombinant Protein Therapeutics CDMO Market

• Richter-Helm BioLogics

• Lonza

• Catalent, Inc

• FUJIFILM Diosynth Biotechnologies

• WuXi Biologics

• Curia Global, Inc.

• Batavia Biosciences B.V.

• HALIX B.V.

• BIOVIAN

• Enzene Biosciences Ltd

Order a free sample PDF of the Recombinant Protein Therapeutics CDMO Market Intelligence Study, published by Grand View Research.

[yo-sostenible]

Desde que fueron identificados por primera vez en el intestino y las heces, los científicos han hallado microplásticos en cada rincón de nuestro cuerpo. El último ha sido el cerebro. Sin embargo, todavía no están claras las consecuencias de esta acumulación para nuestra salud. Los microplásticos son un problema medioambiental y de salud. / Adobe Stock Por Antonio Villarreal No hay semana en la que no aparezca una nueva publicación científica alertando de la presencia de microplásticos en una nueva parte del cuerpo.  Todo ha ido muy rápido desde que, hace 20 años, el biólogo marino Richard Thompson, de la Universidad de Plymouth (Reino Unido), acuñara por primera vez el término tras encontrar en la playa partículas mucho más pequeñas que un grano de arroz. No tardamos mucho en descubrir que estos microplásticos están por todas partes: en el agua que bebemos, en la comida que ingerimos e incluso en el aire que respiramos. Inicialmente, la hipótesis era que los tomábamos a través de la comida o la bebida pero que, eventualmente, eran eliminados a través de las heces o la orina sin provocar mayores problemas. Un trabajo pionero de 2018 fue el primero en identificarlos en el intestino.  Fueron solo ocho participantes, repartidos por todo el mundo, pero con la presencia de estos componentes quedaba claro que el problema tenía una amplitud global. La mayor parte de ellos, además, había consumido pescado, lo que dejaba claro que los hallazgos de Thompson en ecosistemas marinos tenían una relación más que directa con la salud humana. Philipp Schwabl, gastroenterólogo y hepatólogo de la Universidad Médica de Viena y principal autor de aquel estudio, advirtió ya entonces que, aunque hasta la fecha solo habían podido identificarse en esa parte del cuerpo, “las partículas de microplástico más pequeñas pueden entrar en el torrente sanguíneo, el sistema linfático e incluso alcanzar el hígado”. Efecto tóxico de estas partículas Aquel sería el siguiente paso. En la primavera de 2022, un equipo de investigadores holandeses liderados por un inmunólogo español, Juan José García Vallejo, identificó por primera vez microplásticos en la sangre humana. Según detallaba el artículo publicado en Environment International, en concreto, de los 22 donantes de sangre que analizaron en su estudio, 17 tenían restos de PET y poliestireno en su torrente sanguíneo. Son los tipos de plástico más comunes hallados en nuestro organismo, junto a otros dos, el polietileno y el polimetilmetacrilato. “Desde mi punto de vista, deberíamos dejar de catalogar a todos los microplásticos como un único contaminante, ya que el efecto tóxico de un microplástico va a depender de varios factores, tales como su tamaño (a menor tamaño, mayor toxicidad), su forma y, lo más importante, su contenido en aditivos químicos tóxicos asociados al plástico”, explicaba recientemente al SMC Ethel Eljarrat, directora del Instituto de Diagnóstico Ambiental y Estudios del Agua del CSIC. Prácticamente todas las grandes industrias contribuyen al problema, pero no todas tienen los mismos parámetros o controles de calidad. Por ejemplo, se calcula que el 35 % de los microplásticos hallados en los océanos corresponden a la industria textil. Como explica a SINC Raúl González, CEO de la plataforma de moda circular Ecodicta, “gran parte de nuestra ropa está hecha a partir de materiales fósiles, estas fibras sintéticas liberan microplásticos no solo cuando las lavamos, sino también durante cada etapa de la producción textil (hilar, tejer, teñir) y más tarde, cuando se degradan en vertederos o en playas donde acaban muchas prendas desechadas: desde ahí, los microplásticos entran en la cadena trófica marina, acumulándose en los peces que luego consumimos”, y junto a ellos, muchos otros compuestos asociados a estos procesos industriales que siguen adheridos al plástico, como los disruptores endocrinos. Página 1 de 1, Genially sin título Fuente Eurofins Environment...

[eurofinsadvinus]

📢 𝐕𝐚𝐥𝐢𝐝𝐚𝐭𝐞𝐝 𝐈𝐧 𝐕𝐢𝐭𝐫𝐨 𝐏𝐨𝐭𝐚𝐬𝐬𝐢𝐮𝐦 𝐑𝐞𝐥𝐞𝐚𝐬𝐞 𝐀𝐬𝐬𝐚𝐲 𝐟𝐨𝐫 𝐋𝐢𝐩𝐨𝐬𝐨𝐦𝐚𝐥 𝐟𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐀𝐦𝐩𝐡𝐨𝐭𝐞𝐫𝐢𝐜𝐢𝐧 𝐁 Eurofins Bioanalytical Services India offers a validated in vitro assay specifically tailored for liposomal Amphotericin B to quantify potassium release from red blood cells. The assay is optimized for 96-well plate format and leverages ICP-MS for potassium quantification achieving enhanced sensitivity and precision. This assay is ideally suited for Bio-IND applications requiring robust comparability between reference listed drug (RLD) and test formulations. 📩 For detailed assay insights or collaboration opportunities: bd.bioanalysis@advinus.eurofinsasia.com

[eurofinsindia]

Congratulations to the entire Eurofins Team on achieving satisfactory Z-Scores in the PT round for Iron, Vitamin B9, and B12 in Vitamin Mineral Premix for fortified rice kernel (FRK), conducted by FSSAI-AOAC (India section).   To get your products tested with Eurofins Analytical Services, click here: https://www.eurofins.in/food-testing

[healthcare-updates-with-sns]

Forensic Technology Market: Industry Trends and Forecast 2024-2032

The Forensic Technology Market was valued at USD 21.32 billion in 2023 and is projected to reach USD 54.18 billion by 2031, growing at a compound annual growth rate (CAGR) of 12.6% during the forecast period from 2024 to 2031. This remarkable growth is being fueled by a surge in criminal activities, advancements in biometric and DNA analysis technologies, and increased government investment in modernizing forensic infrastructure.

Market Description

Forensic technology plays a crucial role in criminal investigations, offering scientific techniques to collect, preserve, and analyze evidence. With the rise in sophisticated crimes and digital offenses, law enforcement agencies are increasingly relying on advanced forensic tools to solve cases efficiently. Technological developments such as automated fingerprint identification systems (AFIS), next-generation sequencing, and digital forensics are revolutionizing how investigations are conducted. The market is expanding not just in traditional areas like ballistics and DNA profiling, but also in newer fields including cybersecurity forensics and facial recognition.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/3947

Regional Analysis

North America holds the largest share of the forensic technology market, attributed to the presence of advanced infrastructure, strong funding support, and widespread use of forensic tools in law enforcement.

Europe follows closely, driven by technological innovation and strict legal frameworks that encourage evidence-based investigation.

Asia-Pacific is projected to witness the fastest growth during the forecast period. Factors such as rising crime rates, increasing awareness, and governmental initiatives to upgrade forensic departments are contributing to market growth in countries like India, China, and Japan.

Latin America and Middle East & Africa are gradually adopting forensic technologies, with demand expected to increase as infrastructure develops and crime detection becomes a top priority.

Market Segmentation

By Type:

Biometric Devices

Digital Forensics

Ballistic Forensics

DNA Profiling

Others

By Application:

Law Enforcement Agencies

Healthcare

Banking & Financial Institutions

Government

Others

By End-User:

Public Sector

Private Sector

KEY PLAYERS:

The key market players include Eurofins Medigenomix GmbH, Agilent Technologies, NMS Labs, Thermo Fisher Scientific, Inc., Forensic Fluids Laboratories, Forensic Pathways, SPEX Forensics, LGC Forensics, Pyramidal Technologies Ltd, GE Healthcare & other players.

Key Highlights

Rapid technological advancements in DNA sequencing and biometric analysis

Growing demand for digital forensic solutions amid rising cybercrimes

Increased government initiatives to modernize forensic laboratories

Integration of artificial intelligence (AI) and machine learning in forensic processes

Expansion of forensic services across emerging economies

Future Scope

The forensic technology market is poised for significant evolution as new scientific techniques emerge to enhance crime detection and evidence analysis. Future innovations are likely to center around automation, AI-driven data interpretation, and portable forensic devices, enabling faster and more accurate results at crime scenes. Additionally, the integration of cloud computing and blockchain for secure storage and transfer of forensic data is expected to become more mainstream. As governments continue to invest in public safety and judicial efficiency, the demand for next-generation forensic tools will escalate across sectors.

Conclusion

The global forensic technology market is undergoing a transformative shift fueled by rising criminal complexities and the need for reliable, scientific investigation methods. As the market continues to expand across regions and industries, stakeholders are focusing on innovation, collaboration, and infrastructure development to meet growing demand. With sustained technological advancements and strong support from law enforcement agencies, the forensic technology industry is set to become a cornerstone of modern criminal justice systems.

Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Other Related Reports:

Cell Viability Assay Market

Medical Power Supply Market

Post Traumatic Stress Disorder Treatment Market

MRI Guided Neurosurgical Ablation Market

[walkingghotst]

North America Genomics Market Growth and Recent Trends by Forecast 2027

The North America Genomics market is expected to reach US$ 20,348.43 million in 2027 from US$ 7,669.34 million in 2019. The market is estimated to grow with a CAGR of 13.3% from 2020-2027.

NORTH AMERICA GENOMICS MARKET SEGMENTATION

North America Genomics Market: By Technology

Sequencing

Microarray

Polymerase Chain Reaction

Nucleic Acid Extraction and Purification

Others

North America Genomics Market: By Product and Services

Instruments/Systems

Consumables

Services

North America Genomics Market:By Application

Diagnostics

Drug Discovery and Development

Precision/Personalized Medicine

Agriculture & Animal Research

Others

North America Genomics Market: By End User

Research Centers

Hospitals & Clinics

Biotechnology & Pharmaceutical Companies

Others

North America Genomics Market: By Country

North America

US

Canada

Mexico

 North America Genomics Market: Company Profiles

Illumina, Inc.

Danaher

F. HOFFMANN-LA ROCHE LTD.

BIO-RAD LABORATORIES INC.

General Electric Company

THERMO FISHER SCIENTIFIC INC.

Agilent Technologies, Inc.

Eurofins Scientific

QIAGEN

BGI

Request sample PDF:

https://www.businessmarketinsights.com/sample/TIPRE00004301

North America Genomics Report Scope

Report Attribute        Details

Market size in 2019     US$ 7,669.34 Million

Market Size by 2027    US$ 20,348.43 Million

Global CAGR (2020 - 2027)     13.3%

Historical Data 2017-2018

Forecast period           2020-2027

Gaining a Competitive Edge: North America Genomics

Strategic insights for the North America Genomics market deliver a data-informed examination of the industry's configuration, encompassing current trends, major players, and regional specificities. These insights furnish actionable recommendations, empowering readers to gain a competitive advantage by pinpointing unexploited market niches or formulating distinctive value propositions. By leveraging data analytics, these insights assist industry participants – including investors and manufacturers – in foreseeing market shifts. A future-oriented perspective is paramount, enabling stakeholders to anticipate upcoming market evolutions and strategically position themselves for enduring success within this dynamic North American arena. Ultimately, incisive strategic intelligence equips readers to make well-considered decisions that boost profitability and achieve their commercial goals within the genomics landscape.

Localized Market Understanding: North America Genomics

Comprehending the geographic scope of the North American Genomics market is vital for business operations and competitive standing. Recognizing local variations, such as differing consumer inclinations (e.g., preferences for specific genomic services or data privacy protocols), shifting economic landscapes, and diverse regulatory frameworks, is essential for tailoring strategies for particular markets. Businesses can broaden their market penetration by identifying under-served areas or modifying their offerings to align with local needs. A defined market focus allows for more efficient deployment of resources, precisely targeted marketing initiatives, and enhanced positioning relative to regional competitors, ultimately stimulating expansion within these specific geographic areas.

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027

Analysis By Technology (Sequencing, Microarray, Polymerase chain reaction (PCR), Nucleic Acid Extraction and Purification, and Others), Product & Service (Instruments/Systems, Consumables, and Services), Application (Diagnostics, Drug Discovery and Development, Precision/Personalized Medicine, Agriculture & Animal Research, and Others), End User (Research Centers, Hospitals and Clinics, Pharmaceutical & Biotechnology Companies, and Others), and Country

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications

[ananya5400]

The research insight on the dairy testing industry highlights the prominent players in the market. Get known & unknown adjacencies impacting the market for dairy testing.

[australiajobstoday]

Medical Device Data Review Specialist - Package Testing

Company DescriptionEurofins Scientific is an international life sciences company that provides a wide range of analytical testing services to clients across multiple industries. From food and pharmaceuticals to environmental and cosmetic products, Eurofins ensures safety, authenticity, and accuracy. With a global presence and over 900 laboratories, Eurofins is a leader in food, environmental,…

[aitoolswhitehattoolbox]

Medical Device Data Review Specialist - Package Testing

Company DescriptionEurofins Scientific is an international life sciences company that provides a wide range of analytical testing services to clients across multiple industries. From food and pharmaceuticals to environmental and cosmetic products, Eurofins ensures safety, authenticity, and accuracy. With a global presence and over 900 laboratories, Eurofins is a leader in food, environmental,…